Introduction
Primary carotid stenting (PCS) is a technique designed to reduce the complexity, cost, and possibly the risk of carotid angioplasty and stenting (CAS) in patients with severe, symptomatic carotid stenosis.Reference Bussiere, Pelz and Kalapos1,Reference Lownie, Pelz, Lee, Men, Gulka and Kalapos2,Reference Baldi, Zander, Rabellino, Gonzalez and Maynar3,Reference Leonardi, Dall’Olio and Raffi4 At our center, stenting is performed without the deliberate use of angioplasty balloons or embolic protection devices (EPDs). This technique relies on the chronic outward force of self-expanding stents (SESs) to gradually expand the vessel caliber. The goal is not to immediately produce a normal diameter artery but to eliminate the embolic potential of atherosclerotic plaque and to provide adequate cerebral hemispheric blood flow. In patients with appropriate plaque characteristics on CT angiography (CTA) (i.e. predominantly non-calcified plaque), satisfactory long-term morphological results are achievable.Reference Pelz, Lownie, Lee and Boulton5 The number of steps is reduced, fewer costly devices are used, and the avoidance of balloons eliminates significant intra- and post-procedural hemodynamic instability.Reference Bussiere, Lownie, Lee, Gulka, Leung and Pelz6 In our experience, PCS alone is effective in over 80% of patients referred for CAS.Reference Bussiere, Pelz and Kalapos1
Every step during CAS with balloon angioplasty (BA) protocols generates embolic debris, with the most emboli produced by stent deployment, BA, and EPD placement.Reference Almekhlafi, Demchuk and Mishra7,Reference Choi, Saqqur and Stewart8 The primary aim of this study was to establish the number of micro-embolic signals (MES) on transcranial Doppler (TCD ) generated by each step of PCS and to determine the relationship of MES to new DWI lesions on post-procedural magnetic resonance imaging (MRI). The secondary aim was to compare the number of MES and new DWI lesions in the PCS patients to historical controls of standard carotid stenting techniques with BA and EPD use, and the small number of patients in whom BA was deemed to be necessary in our series.
Methods
This is a prospective, single-arm, cohort study, approved by the Health Sciences Research Ethics Board (HSREB) of Western University, London, Ontario, Canada. Eighty-five patients with symptomatic, severe (>70% NASCET) carotid stenosis and able to give informed consent were recruited. Subjects who were unable to undergo an MRI scan or those without an adequate window for TCD monitoring were excluded. Patients with unfavorable plaque morphology on preoperative CTA (thick, circumferential calcification, and little soft plaque) were excluded. The primary authors encountered the cases consecutively, but recruitment was delayed by the COVID-19 pandemic and other logistical factors.
Carotid stenting was performed with intention to use PCS alone for 78 vessels in 76 patients (2 patients had bilateral stenoses). PCS is routinely performed under conscious sedation provided by an anesthesiologist. Patients are placed on dual-antiplatelet medications (ASA and clopidogrel) for at least 48 h. prior to the procedure. Common femoral or radial artery access is used in all patients with systemic heparinization initiated after access is obtained. Activated clotting time is maintained at 2–3 times baseline level. The target common carotid artery is accessed using a 6Fr Envoy guide catheter (Cook, Bloomington, IN), and digital subtraction angiograms (DSAs) are obtained. Under Roadmap guidance, the carotid stenosis is crossed with a 0.014 Transend micro-guide wire (Stryker Neurovascular, Fremont CA), followed by advancement of a SES (Precise PRO RX, 8 mm × 4 cm, Cordis, Fremont CA). No EPD is utilized. Pre-stent BA is performed with a small diameter balloon if there is resistance to stent advancement (2 of 78 vessels). Post-stent BA is performed if the post-deployment DSA shows an unacceptable residual stenosis (21 of 78 vessels). Femoral closure devices (AngioSeal, St Jude Medical, St Paul, MN) are used in most patients. Compression bands are used following transradial procedures. Subjects are monitored overnight in a neuro-observation unit and usually discharged next day after duplex carotid ultrasound. Patients remain on clopidogrel for at least 1–6 months, and ASA indefinitely. Follow-up ultrasounds are performed at 1, 6, and 12 months post-procedure, and then annually.
In nine patients, CAS with BA was performed at the discretion of the operator. This was usually due to a real or anticipated unacceptable morphologic result with PCS alone (>30–40% residual stenosis by NASCET criteria). In these patients, the protocol was identical, with the addition of initial EPD (FilterwireEZ, Boston Scientific, Marlborough, MA) deployment, and balloon (Sterling, Boston Scientific) angioplasty pre- ± post-stent deployment.
TCD was performed throughout the procedure in all patients using a transcranial power M-Mode Doppler machine (ST3; Spencer Technologies, Seattle WA). A high-power (2 MHz) ultrasound probe was fixed to a head frame (Marc 600; Spencer Technologies) for monitoring of the ipsilateral proximal middle cerebral artery at 45–65 mm depth. The interventionalist informed the TCD operator continuously about the progress of the stenting procedure, which was divided into the following seven steps: crossing the arch with the guiding catheter; catheterizing the common carotid artery; crossing the stenosis with the guide wire; crossing the stenosis with the stent; deploying the stent; removing the guide wire; and retrieving the guide catheter. The times of every step, contrast injections, and any unexpected events were recorded. The number and size of TCD emboli (MES) for each step were manually counted, measured, and registered offline by two readers (CM and RA). Signals detected during contrast injections were excluded. Embolus analysis was performed on both the spectrogram and the power M-mode to improve reliability. Embolus signals on the spectrogram were identified visually as unidirectional, short-lasting (<300 ms) signals with an amplitude of >73dB above background and a typical chirping sound. The sizes of the emboli were calculated using the relative energy index of microemboli (REIM) signals, as previously described.Reference Almekhlafi, Demchuk and Mishra7,Reference Choi, Saqqur and Stewart8 An embolus with REIM >1.0 was considered to be malignant. Malignant emboli are those with a diameter >500 um, large enough to occlude small penetrating arteries.
Every patient was assessed for the development of any new or worsening neurological deficit in the first 24 hours post-stenting by the neurointerventional team comprised of neurologists, neurosurgeons, and neuroradiologists. Duplex carotid ultrasound was performed before discharge in all patients. All patients had undergone MRI examinations with DWI within 30 days prior to CAS. Post-procedure MRI with DWI was performed within 24–48 hours in all patients and analyzed by independent neuroradiologists (DP, MS, SP, and MM) who were blinded to the TCD data. The number and location of DWI lesions on the post-stent MRI were compared to the preoperative study. DWI lesions were classified as single or multiple, but the total number was not recorded.
All statistical analysis was done on SPSS Statistics for Windows, version 27 (SPSS Inc., Chicago, Ill). At first, a descriptive analysis was done for all the variables in the dataset and the distribution of continuous variables was checked. The number and intensity of TCD emboli and the number of DWI lesions were analyzed and compared to study variables. Correlation analysis was done to find any relationship between continuous variables, while relationship between categorical variables was assessed through chi-square and Fisher’s exact tests. Most of the continuous variables followed non-normal distribution, so we used nonparametric tests for further analysis. The Mann–Whitney U test was used to assess any difference between number and intensity of TCD emboli in those patients who underwent PCS compared to those who underwent CAS with BA. Similarly relationships of total and malignant MES to pretreatment NASCET stenosis, and the difference between pre- and posttreatment NASCET stenosis were determined and compared those who had new DWI changes and to those who did not have new DWI changes. Negative binomial regression was done to assess the relationship of TCD emboli count and size of TCD emboli with the type of procedure and level of pre- and posttreatment NASCET stenosis. Logistic regression analysis was done to find association of new DWI lesions with other study covariates. Results were expressed as absolute numbers, percentages, mean with standard deviation, median with interquartile range, odds ratio with 95% confidence interval, and effect size. A two-tailed p-value of 0.05 was considered as significant for all the tests.
Results
A total of 85 patients were recruited for the study. The mean age was 67.8 years. There were 64 males (75.2%) and 21 (24.7%) females. All patients were symptomatic and had severe (>70%) internal carotid artery stenoses by NASCET criteria. Co-morbidities between those patients who underwent PCS alone and those who required BA were similar. Two patients had bilateral stenting procedures performed on the same date and were considered as single patients.
TCD data were not available in 8 procedures, leaving 79 procedures (in 77 patients) for analysis. Seventy-six patients underwent PCS (two bilaterally), without deliberate use of angioplasty balloons unless required for initial passage of the SES through the stenosis or failure of adequate stent expansion. BA was required in three of these patients. Nine patients underwent CAS with BA and EPD use due to real or anticipated unacceptable morphologic results. In the group of 12 BA patients, 7 required pre only, 2 required post only, and in 3 patients, both pre- and post-stent BA were required.
The mean clinical follow-up is 4 years, 3 months (median 3.5 years). Clinically, one patient in the PCS group (1.3%) and one patient in the CAS with BA group (11%) experienced a transient ischemic attack (TIA) within 48 hours of the procedure. One patient in the CAS with BA group experienced post-procedural hypotension (11%). Another patient in the CAS with BA group sustained a NSTEMI at 2 weeks post-procedure and died 27 days post-procedure. Another patient in the CAS with BA died of cardiac failure 5 weeks post-procedure. No other 30-day clinical complications were observed. The 30-day major stroke and death rate differed significantly between PCS and CAS, favoring PCS (p = 0.01).
With regard to delayed stent concerns, eight patients in the PCS group (10.6%) restenosed and required delayed angioplasty, while three in the BA group (25%) also required delayed angioplasty for restenosis. The time intervals ranged from 2.5 months out to 6 years post-procedure. The recurrent stenoses were severe or approaching 70% by NASCET criteria. One of these had suffered an infarct 5 months after the initial procedure. The other 10 patients were asymptomatic. Three stents (two post-PCS and one post-BA) were found occluded (4.1%) during follow-up. Two were asymptomatic, but one at 9 months post-procedure suffered a fatal infarct. Two others in the PCS group developed thrombus within the stent. One resolved with anticoagulation, but one experienced TIAs at 1 and 2 months post-procedure, and a new ipsilateral stroke at 3 months. He later died of an unrelated medullary infarct at 13 months.
The results of the TCD examinations are shown in Tables 1, 2, and 3. The average number of MES generated per procedure is 114. The average number of malignant emboli was 44. Overall, 61.4% of MES are nonmalignant and 38.6% are malignant. The mean proportion of MES generated during each stage out of total MES is given in the tables. The most MES are generated by stent deployment (mean = 57.7, mean proportion = 53.5%). For CAS with BA, additional total MES are generated with balloon inflation (mean = 22.8, mean proportion = 22.5%) and EPD deployment (mean = 11.2, mean proportion = 14.8%) (Tables 1 and 2). Malignant emboli account for 46.1% of MES for aortic arch catheterization, 26.9% for stent deployment, 38.1% for balloon inflation, and 49.1% for EPD deployment (Table 2). There is no significant association between overall MES count and: PCS; CAS with BA; level of pretreatment and posttreatment stenosis on negative binomial regression. Similarly, no association is found between overall malignant MES and: PCS; CAS with BA; level of pretreatment and posttreatment stenosis. However, there are significant differences in the total and malignant MES generated during different stages of PCS and CAS with BA (Table 3). Comparing PCS and CAS with BA, more total/malignant MES are generated during aortic arch/common carotid artery catheterization in CAS with BA. The total number of MES generated during stent deployment is greater with PCS, and overall malignant MES generation is greater in CAS with BA. There is no other significant difference in MES generation during the remaining stages of PCS and CAS with BA (Table 3).
Descriptive analysis of total and malignant MES at the most relevant stages of PCS and CAS
Mean proportion of MES and benign/malignant proportions at the most relevant stages of PCS and CAS
Significant differences between PCS and CAS for generation of MES
Of the 12 patients who required BA, those who underwent pre-stent BA averaged 59 malignant and 99 total MES; those who underwent post-stent BA averaged 59 malignant and 156 total MES; and those who underwent both pre- and post-BA averaged 39 malignant and 107 total MES.
Table 4 summarizes the relationship of new DWI lesions with other study covariates between PCS and CAS with BA. Overall, new DWI changes were seen in 37 patients (45%). Thirty of 37 patients (81%) had lesions in the same territory as the stented artery. Seven of 37 patients (19%) had lesions in a different territory, and 9 of 37 patients (24%) had DWI lesions in multiple territories. In 16 of the 37 patients (43%), multiple DWI lesions were in the same territory, 10 of which (63%) were on the same side as the stented artery. There were statistically significant differences between: new DWI lesions and pretreatment NASCET stenosis (p = 0.002); benign MES (p = 0.034) and total number of MES (p = 0.009). There are no statistically significant differences for new DWI lesions between PCS and CAS with BA and EPD use.
Relationships of new DWI lesions and study covariates
* Significant at 5% level of significance.
In the 12 patients who underwent BA, 5 of the 7 patients who underwent pre-stent BA (71%) had new DWI lesions; neither of the 2 post-stent BA patients had new DWI lesions, and 1 of the 3 pre- and post-stent BA patients (33%) had new DWI lesions.
Discussion
CAS with BA is now widely regarded as an alternative intervention for carotid bifurcation atherosclerotic disease.Reference Brott, Howard and Roubin9 It has, however, been shown to result in higher post-procedural stroke rates than carotid endarterectomy (CEA),Reference Brott, Howard and Roubin9,Reference Hill, Brooks and Mackey10,Reference Bonati, Lyrer, Ederle, Featherstone and Brown11 despite the routine use of EPDs designed to capture embolic debris generated by the endovascular maneuvers. Each step of CAS with BA generates emboli as detected by intraprocedural TCD analysis.Reference Almekhlafi, Demchuk and Mishra7,Reference Ackerstaff, Suttorp and van den Berg12 Most embolic debris results from stent deployment, BA, and EPD placement.Reference Almekhlafi, Demchuk and Mishra7,Reference Ackerstaff, Suttorp and van den Berg12,Reference Skjelland, Krogh-Sorensen, Tennoe, Bakke, Brucher and Russell13 Despite the use of EPDs, new ischemic lesions on post-procedural DWI are seen in up to 80% of patients undergoing CAS, although most are asymptomatic.Reference Almekhlafi, Demchuk and Mishra7,Reference Gargiulo, Sannino, Stabile, Perrino, Trimarco and Esposito14 Although credited with reducing the incidence of strokes during CAS, many authors have reported complications from EPD use and some have questioned their overall utility.Reference Cremonesi, Manetti, Setacci, Setacci and Castriota15,Reference Tallarita, Rabinstein and Cloft16,Reference Binning, Maxwell and Stofko17
In 2013, a report from the Calgary groupReference Almekhlafi, Demchuk and Mishra7 used procedural TCD and post-procedural DWI to investigate the relationship of MES to DWI lesions using CAS with BA. They found a median MES signal count of 212 (108 benign and 80 malignant) and new DWI lesions in 80% of patients (70% ipsilateral). The highest number of malignant MES was observed during stent and EPD deployment, and there was a significant relationship between malignant emboli and new DWI lesions.
Others have investigated the safety of CAS with BA and EPDs using intraprocedural TCD monitoring. The mean total number of MES generated per procedure has ranged from 116 to 276 despite the use of EPDs.Reference Almekhlafi, Demchuk and Mishra7,Reference Ackerstaff, Suttorp and van den Berg12,Reference Skjelland, Krogh-Sorensen, Tennoe, Bakke, Brucher and Russell13,Reference Gargiulo, Sannino, Stabile, Perrino, Trimarco and Esposito14,Reference Vos, van den Berg and Ernst18,Reference Chen, Iguchi, Garami, Malkoff and Smalling19,20,Reference Rosenkranz, Fiehler and Niesen21,Reference van Heesewijk, Vos, Louwerse, van den Berg and Overtoom22 In all studies, the most MES were generated by stent deployment, followed by BA and EPD deployment, similar to our experience. In one study, more MES were generated in patients with EPD use than in a comparison group without EPD use.Reference Vos, van den Berg and Ernst18 Our average number of 114 MES (70 benign and 44 malignant) per procedure compares favorably with these historical controls. There were significantly more malignant MES in our small series of CAS with BA patients than with PCS, although total MES were not significantly different.
We observed new DWI lesions in 36 patients, 44.5% of PCS and 54.5% of CAS with BA patients, a nonsignificant difference. We found a correlation between the total number of MES and new DWI lesions, similar to the Calgary experience. Despite the prevalence of new DWI lesions, only one patient experienced a TIA and none of the patients suffered an acute stroke. The number of new DWI lesions reported following CAS ranges from 15 to 80%.Reference Almekhlafi, Demchuk and Mishra7,Reference Skjelland, Krogh-Sorensen, Tennoe, Bakke, Brucher and Russell13,Reference Gargiulo, Sannino, Stabile, Perrino, Trimarco and Esposito14,Reference van Heesewijk, Vos, Louwerse, van den Berg and Overtoom22 Many series have included asymptomatic patients with stenoses less than 70% by NASCET criteria. Considering that all of our patients were symptomatic with severe ipsilateral stenoses, our figures are quite acceptable.
Our 30-day stroke and death rate of 1.2% compares favorably to other large series with short-term stroke and death rates of 4–6%.Reference Brott, Howard and Roubin9,Reference Hicks, Nejim, Obeid, Locham and Malas23
PCS may not be appropriate for all patients. We selected our patients based on CTA plaque morphology,Reference Pelz, Lownie, Lee and Boulton5 particularly those with low calcification scores and visible soft plaque. Circumferential calcification has been identified as a risk factor for distal embolic complications in CAS.Reference Fanous, Natarjan and Jowdey24 These patients are more suited to CEA. PCS has been shown to reduce the incidence of hemodynamic instability,Reference Bussiere, Lownie, Lee, Gulka, Leung and Pelz6 and avoidance of aggressive BA, particularly post-stent dilatation, may also lessen the incidence of neurological events up to 30 days post-procedure.Reference Ziapour, Schermerhorn, Iafrati, Suarez, TourSavadkohi and Salehi25 Several studies have advocated the safety and utility of CAS without BA.Reference Petr, Brinjikji, Murad, Glodny and Lanzino26,Reference Ogata, Sonobe and Kato27 and unprotected CAS with BA.Reference Baldi, Zander, Rabellino, Gonzalez and Maynar3,Reference Leonardi, Dall’Olio and Raffi4,Reference Binning, Maxwell and Stofko17,Reference Ogata, Sonobe and Kato27
There are limitations to our study, a small series of patients from a single center. Selection of patients for PCS was made primarily by CTA plaque morphology, introducing possible selection bias. Although an attempt was made to recruit patients consecutively, logistical challenges of the COVID-19 pandemic resulted in significant disruptions and delays. Multiple operators with different levels of experience performed the PCS and CAS procedures. There was a large difference in the numbers of PCS (75) and CAS with BA (12) procedures, making direct comparisons between groups in our series of limited validity. TCD data were unavailable in 4 of 12 (33%) of BA cases, compared to lack of TCD data in only 4 of 75 (5%) PCS cases, also introducing potential bias. We used a stent with an open-cell design, and delayed embolization through the stent struts can occur.Reference Timaran, Rosero and Higuera28,Reference Texakalidis, Giannopoulos, Kokkinidis and Lanzino29 DWI lesions occurring more than 24–48 hours after the procedure may be missed. The avoidance of BA in PCS may lead to a higher rate of restenosis than the 4–10% at 1 year using CAS with BA.Reference Groschel, Reicker, Schulz, Ernemann and Kastrup30,Reference Kumar, Batchelder and Saratzis31 There is however no association between restenosis and stroke for CAS with BA.Reference Groschel, Reicker, Schulz, Ernemann and Kastrup30 Our rate of delayed stent occlusion in the PCS group (2.7%) is similar to that reported with CAS and BA (3%),Reference Buhk, Wellmer and Knauth32 and only one patient became symptomatic.
Conclusion
We believe that PCS is a safe and effective method to treat severe, symptomatic carotid stenosis in selected patients, based on preoperative plaque morphology on CTA. It generates fewer MES on intraprocedural TCD and an acceptable number of new DWI lesions on post-procedural MRI compared to historical controls of CAS using BA and EPDs. In patients with appropriate plaque characteristics on preoperative CTA, PCS can be considered a safe, faster, and less costly alternative to CAS with BA.
Acknowledgments
Solo K, Pandey S, Sharma M, Lee DH, Boulton M, Mayich M, Kiwan R, Salehi F, Johnson P, and Shariatzadeh A for TCD and carotid intervention performance, data collection, and analysis.
Conflicts of Interest
The authors declare no conflicts of interest.
Disclosures
None.
Open access
